Table 1
Pharmachild (N=5571) | NR UK (N=1537) | NR Germany (N=3243) | NR Portugal (N=112) | TOTAL (N=10463) | |
|---|---|---|---|---|---|
Age at onset | 5.4 (2.4 – 10.0) | - | 7.2 (3.1-11.4) | 6.3 (2.5-10.9) | - |
Age at JIA Diagnosis | 6.2 (2.8 – 11.0) | 5.5 (2.1-10.2) | 8.2 (4.0-12.3) | 7.3 (3.3-12.3) | - |
Disease duration at the last follow-up | 4.9 (2.5 – 8.2) | 5.4 (2.7 – 8.8) | 5.2 (3.1-8.4) | 3.0 (0.5-9.6) | - |
Therapy with MTX only | 1365 (24.5) | 503 (32.7) | 1132/3134 (36.1) | 0 (0.0) | 3000/10354 (29.0) |
Therapy with only one Biologic Drug + MTX | 2378 (42.7) | 862 (56.1) | 1545/3134 (49.2) | 27 (24.1) | 4812/10354 (46.5) |
Therapy with more than one Biologic + MTX | 872 (15.6) | 141 (9.2) | 340/3134 (10.8) | 78 (69.6) | 1431/10354 (13.8) |
Nr. patients with ESI or AE | 1070 (19.2) | 1093 (71.1) | 1163(37.1) | 27 (24.1) | 3353 (32.4) |
Nr. patients with ESI | 496 (8.9) | 230 (15.0) | 249 (7.9) | 5 (4.5) | 980 (9.5) |
Nr. patients with AE | 729 (13.1) | 1075 (69.9) | 1069 (34.1) | 24 (21.4) | 2897 (28.0) |